Taiwan Healthcare+ ***Together We Challenge the International Biotech World Cup
The Taiwan Healthcare+ International Entrance Platform was officially launched on 12/23, bringing together 100 top companies and organizations in three major fields, namely, biotechnology, pharmaceuticals, innovative medical devices, and healthcare, with the support of the Ministry of Health and Welfare. Taiwan Healthcare + International Entrance Platform" was officially announced on 12/23, bringing together 100 top enterprises and organizations in the three major fields of biotech-pharmaceutical, innovative medical materials and medical care, and was launched by Vice President Chen Chien-Jen, Founder Wang Jin-Ping of the Healthcare Council, Minister Lin Zao-Yan of the Ministry of Health and Welfare, as well as representatives from THP's medical institutes and various fields of biotech industry, and countries' trade and commerce*** to formally launch on-line to the international services, and the 19th National Biotech and Healthcare Quality Award Ceremony was also held to award the 2016 ****30 award-winning medical The 19th National Biotech Medical Quality Award Ceremony was also held to award the 30 winning medical teams and biomedical products in 2016***. Taiwan Healthcare+ Biomedical Innovation and Technology Exhibition was held at the same time, with nearly 50 new and innovative technology products on display.
Hocena Cancer and Chronic Disease Drug Wins National Innovation Award
Hocena has won the 13th National Innovation Award for "Clinical Progress of Hocena - A New Cancer Drug and Chronic Disease Drug". In addition to the human clinical trials for lung cancer, Antroquinonol has also recently launched a large-scale global Phase II human clinical trial for pancreatic cancer, and will actively intervene in the treatment of first-line pancreatic cancer patients by means of a combination therapy model, in order to capture the global market for pancreatic cancer drugs after confirming the efficacy of human trials. In addition, Antroquinonol was also granted orphan drug designation by the US FDA in 2015 for the treatment of pancreatic cancer, acute myelogenous leukemia (leukemia), and hepatocellular carcinoma, and is now undergoing clinical trials in pancreatic cancer, and has the opportunity to apply for a marketing authorization (NDA) after completing Phase II clinical trials to confirm efficacy.
Triumph's R&D team selected commonly used drugs, low bioavailability, and short-acting key ingredients, and utilized its own Trasnsdermal DDS technology to focus on the development of a patch product that focuses on geriatric and pediatric disorders such as ADHD and Alzheimer's Disease, and a new dosage form of the patch that provides long-lasting efficacy, consistent blood levels over time, and increased ease of use for patients and medication. Increase the convenience of use and medical advice for patients
ITRI's new biotech company, Jusheng Biomedical, is a niche nanomedicine developerJusheng Biomedical's IOP Injection iron oxide nanomedicine has been selected by the Center for Drug Evaluation (CDE) as an indicator case this year. In February, the Industrial Development Bureau of the Ministry of Economic Affairs (MOEA) evaluated that it complied with the "Regulations on the Development of the Biotechnology and Pharmaceutical Industry," and in the same month, Jusheng Biomedical began to collaborate with the Taipei General Chamber of Commerce to conduct a Phase I clinical trial of IOP Injection. Phase I clinical trial of IOP Injection is underway. The market demand for iron supplementation in renal disease patients is very large, with the annual market for intravenous iron reaching more than $1.6 billion worldwide. IOP Injection nano iron oxide drug can satisfy this rapidly increasing demand for iron supplementation through a single injection of iron, eliminating the need for multiple treatments. The use of polyethanol as an excipient is safer and less likely to cause allergic side effects than similar products, and can prevent severe allergic deaths.
Enterovirus 71 vaccine for infants 2-6 months of age
Enterovirus 71 is the most threatening of all types of enterovirus to young children. Because the immune system of infants under 6 months of age is not yet mature, KIA Vaccines developed an enterovirus 71 vaccine for infants 2-6 months of age, the only vaccine in the world to be developed with clinical data for infants 2-6 months of age.
Chuan Sheng Biotech's Anti-Allergy Antibody New Drug
The FB825 (Anti-CεmX) Anti-Allergy Antibody New Drug in collaboration with Academia Sinica has obtained the U.S. Complete Drug and Efficacy Patent (8,460,664), and in the global Anti-CεmX treatment of allergic diseases in a huge market for new drugs, in-vivo, in-vivo, in-vivo and human testing has been completed, as well as safety related tests. Anti-CεmX antibody can directly kill IgE-expressing B-cells and block IgE production, which has the potential to prevent and treat allergic diseases, and is the only new anti-allergy antibody that can rival Xolair in the world.
CCHK develops small molecule functional peptide "Kefir Peptide" CCHK was awarded the 13th National Innovation Award for the "Novel Kefir Peptide Application Development in Health Industry".
|